Global Pharma Pipeline

Global pharma at value: Roche, AZN, MRK, GSK, TAK — deep pipelines, patent cliff fears

Total Return

+37.2%

Sharpe Ratio

0.55

Max Drawdown

-17.3%

Win Rate

52.3%

Alpha

-12.0%

Comp. Score *

0.07

Risk Parameters

Max Allocation7.1%

Stop Loss17.3%

Take Profit5.6%

Max DD Tolerance17.3%

Rebalanceweekly

Execution Guidance

Order TypeLimit

Entry RuleBuy 0.5% below market in uptrend.

TimingSAFE TO BUY. *

ScalingEnter in 3 tranches over 1-2 weeks.

Positions — Vol-Adjusted Sizing

Symbol	Action	Vol	Stop Loss	Take Profit	Size	Links
RHHBY	BUY	26%	19.0% below entry	6.1% above entry	6.5%	TV YH
BAYRY	BUY	39%	28.7% below entry	9.2% above entry	4.3%	TV YH
NVS	BUY	20%	14.7% below entry	4.7% above entry	8.4%	TV YH
TAK	BUY	20%	14.4% below entry	4.6% above entry	8.6%	TV YH
AZN	BUY	25%	17.9% below entry	5.8% above entry	6.9%	TV YH
MRK	BUY	27%	19.9% below entry	6.4% above entry	6.2%	TV YH
LLY	BUY	38%	27.8% below entry	8.9% above entry	4.4%	TV YH

▶ For Passive Investors (Buy & Hold)

This strategy has moderate long-term potential but requires monitoring. - Take profit: Rebalance when any position exceeds 2x its target weight. Trim back to target, redeploy to underweight positions. - Stop loss: NO price-based stop loss. This strategy recovered from -21% drawdown to return 68% long-term. - Exit rule: Review annually. Exit if strategy underperforms its benchmark for 3 consecutive years.

Avg 5Y Return

39.7%

Avg 5Y Sharpe

0.27

10Y Return

68.3%

10Y Sharpe

0.16

HODL Composite

0.25

Consistency

82%

Suitable for passive